Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

Paeds Vivasrheumatology-musculoskeletal-and-sports

Paeds Vivas · rheumatology-musculoskeletal-and-sports

Juvenile idiopathic arthritis: Viva

Branching clinical structured oral on juvenile idiopathic arthritis, covering the ILAR classification with the seven categories and the oligoarticular dominance, the chronic anterior uveitis and the three-monthly slit-lamp screening in the high-risk child, the methotrexate at ten to fifteen milligrams per square metre per week, the etanercept and adalimumab biologics, the Wallace clinically inactive disease criteria, and the treat-to-target TREAT trial.

branching clinical structured oral5 min readVerification in progress

Target exams

RACP DWERACP DCEMRCPCH Clinical
On this page
Study tools

Target exams

RACP DWERACP DCEMRCPCH Clinical
Prompt
A three-year-old girl presents with a swollen right knee for ten weeks, stiff in the morning and improving with activity. She is afebrile and well, with the antinuclear antibody positive and the rheumatoid factor negative. The examiner asks how you frame the problem, how you classify the disease, what the slit-lamp shows, and how your stepwise treat-to-target management proceeds, with deliberate probes into the methotrexate toxicity and the septic-arthritis mimic.

This is a branching oral built to probe the reasoning that holds the classification, the uveitis and the treat-to-target therapeutics at the centre, and to expose the candidate who has memorised the headline without the safety-critical corners. The questions escalate from the framing to the classification, the uveitis, the methotrexate and the biologics, with deliberate probes into the septic-arthritis mimic and the biologic infection. [2]

Opening question: framing the problem

The examiner opens with the swollen knee for ten weeks and asks: how do you frame this problem in a single sentence, and what is your first step? [2]

A strong answer names the oligoarticular juvenile idiopathic arthritis from the ten-week duration, the morning stiffness and the single joint, and states that the first step is the slit-lamp for the uveitis and the exclusion of the mimics. [2]

Model answer. This child has the oligoarticular juvenile idiopathic arthritis from the arthritis of one joint for more than six weeks in a child under sixteen, with the morning stiffness that improves with activity. The first step is the slit-lamp for the chronic anterior uveitis, because she is young, antinuclear-antibody positive and oligoarticular, which is the highest-risk profile, and the full joint examination and the exclusion of the septic arthritis and the mimics. [1][2]

Probe one: the classification

The examiner presses: describe the ILAR classification, and tell me which subtype is the commonest and what the persistent-versus-extended split means. [1]

Paediatrics Fellowship Pro

Continue reading

You have read the opening of this viva. The complete unit — every section and its primary-source references — is part of the Paediatrics Fellowship fellowship library.

Sign in to continueSee pricing
References9ShowHide
  1. [1]Petty RE, Southwood TR, Manners P, et al International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001 J Rheumatol, 2004.PMID 14760812
  2. [2]Ravelli A, Martini A Juvenile idiopathic arthritis Lancet, 2007.PMID 17336654
  3. [4]Giannini EH, Brewer EJ, Kuzmina N, et al Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial N Engl J Med, 1992.PMID 1549149
  4. [5]Lovell DJ, Giannini EH, Reiff A, et al Etanercept in children with polyarticular juvenile rheumatoid arthritis N Engl J Med, 2000.PMID 10717011
  5. [6]Wallace CA, Giannini EH, Spalding SJ, et al Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis Arthritis Rheum, 2012.PMID 22183975
  6. [7]Wallace CA, Ravelli A, Huang B, et al. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis using the OMERACT filter J Rheumatol, 2006.PMID 16482643
  7. [8]Constantin T, Foeldvari I, Anton J, et al Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative Ann Rheum Dis, 2018.PMID 29592918
  8. [9]Nordal E, Rypdal V, Christoffersen T, et al. Incidence and predictors of uveitis in juvenile idiopathic arthritis in a Nordic long-term cohort study Pediatr Rheumatol Online J, 2017.PMID 28821293
  9. [11]Horneff G, Minden K, Rolland C, et al. Efficacy and safety of TNF inhibitors in the treatment of juvenile idiopathic arthritis: a systematic literature review Pediatr Rheumatol Online J, 2023.PMID 36829225
Paediatrics Fellowship Pro

$29/ monthor $279 / year

The complete Paediatrics Fellowship library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousJuvenile dermatomyositis — branching vivarheumatology-musculoskeletal-and-sportsNextMusculoskeletal examination and the limping child — branching vivarheumatology-musculoskeletal-and-sports